ストックスクリーナーアプリを入手
67.91
0.34%
-0.23
アフターアワーズ：
68.82
0.91
+1.34%
前日終値:
$68.14
開ける：
$67.87
24時間の取引高:
3.58M
Relative Volume:
1.36
時価総額：
$13.01B
収益：
$353.78M
当期純損益:
$-805.69M
株価収益率:
-16.22
EPS:
-4.1869
ネットキャッシュフロー:
$-597.61M
1週間 パフォーマンス:
-9.75%
1か月 パフォーマンス:
-12.79%
6か月 パフォーマンス:
+38.37%
1年 パフォーマンス:
+84.29%
1日の値動き範囲:
$67.10
$69.50
1週間の範囲:
$67.10
$76.81
52週間の値動き範囲:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
67.91 | 13.06B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.67 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-11 | 開始されました | Bernstein | Outperform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
Insights Ahead: BridgeBio Pharma's Quarterly Earnings - Benzinga
BridgeBio to Participate in March Investor Conferences - The Manila Times
Biotech BridgeBio plans three March investor conference chats - Stock Titan
Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?BridgeBio Pharma (NASDAQ:BBIO), BorgWarner (NYSE:BWA), Expedia Group (NASDAQ:EXPE), Flutter Entertainment ( - Benzinga
BridgeBio Pharma, Inc. $BBIO Shares Sold by HighTower Advisors LLC - MarketBeat
BridgeBio Pharma Inc (BBIO) Stock Price, Quote, News & History - Benzinga
BridgeBio Pharma Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BridgeBio (BBIO) Shares Dip After UBS Summit Withdrawal - GuruFocus
16,893 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by L & S Advisors Inc - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $7.74 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - Defense World
Bank of America Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO - Defense World
HC Wainwright Boosts Earnings Estimates for BridgeBio Pharma - MarketBeat
NEOS Investment Management LLC Has $5.02 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CFO Sells 13,600 Shares of Stock - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Director Randal Scott Sells 10,000 Shares - MarketBeat
BridgeBio Pharma director Scott sells $754k in BBIO stock - Investing.com
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock By Investing.com - Investing.com Canada
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock - Investing.com
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
BridgeBio earnings up next: Can pipeline wins fuel growth? By Investing.com - Investing.com Canada
BridgeBio earnings up next: Can pipeline wins fuel growth? - Investing.com Australia
BridgeBio Pharma, Inc. $BBIO Shares Sold by Readystate Asset Management LP - MarketBeat
Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact - Insider Monkey
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00 - MarketBeat
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - The Manila Times
BridgeBio Pharma, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative
BBIO: Today's Analyst Rating Insights by HC Wainwright & Co. | B - GuruFocus
BBIO stock surges 17% pre-market today – what’s fueling the rally? - MSN
Is BridgeBio Pharma Inc. still a buy after recent gainsJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - mfd.ru
Published on: 2026-02-15 17:09:25 - mfd.ru
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), American Well (AMWL) and BridgeBio Pharma (BBIO) - The Globe and Mail
Is BridgeBio Pharma Inc. a stock for growth or value investorsJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio Pharma, DoorDash, Nvidia, Rio Tinto: What brokers said this week - Proactive financial news
Is BridgeBio Pharma Inc. a speculative investment2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer - MarketBeat
BBIO: Oppenheimer Raises Price Target for BridgeBio Pharma | BBI - GuruFocus
BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo - Morningstar
Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating - marketscreener.com
BBIO: Wells Fargo Raises Price Target to $98 While Maintaining 'Overweight' Rating | BBIO Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
BridgeBio Pharma stock hits all-time high at 84.51 USD By Investing.com - Investing.com Canada
BBIO Stock Surges 19% With A 5-day Spree On Positive Phase 3 Trial Data - Trefis
Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026 - Meyka
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
Bridgebio Pharma Inc (BBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Apuli Maricel | Chief Accounting Officer |
Feb 17 '26 |
Sale |
74.31 |
510 |
37,898 |
123,945 |
| Trimarchi Thomas | President and CFO |
Feb 17 '26 |
Sale |
74.72 |
13,600 |
1,016,147 |
336,585 |
| Scott Randal W. | Director |
Feb 17 '26 |
Option Exercise |
16.75 |
10,000 |
167,500 |
21,589 |
| Scott Randal W. | Director |
Feb 17 '26 |
Sale |
75.46 |
10,000 |
754,557 |
11,589 |
2.25%
0.47%
大文字化:
|
ボリューム (24 時間):